Janssen Search
Search results
Cancer Interception
Cancer Interception “We want to understand what turns healthy cells into cancerous cells. This critical information will help us develop groundbreaking products to interrupt the process.” Peter F. Lebowitz, M.D., Ph.D. Global Therapeutic Area Head, ...
Marco Mohwinckel
Marco Mohwinckel is partner at Janssen Healthcare Innovation (JHI) in Europe, Middle East and Africa (EMEA). Prior to taking on this role, Marco was heading up the Neuroscience Business Unit and was a member of the United Kingdom Management Committee of ...
Mark Oswald
Mark Oswald brings more than twenty years of combined technical leadership, software development, program and product management and technology consulting experience. At Janssen Healthcare Innovation (JHI), Mark is responsible for leading the global ...
Cardiovascular, Metabolism & Retina
Cardiovascular, Metabolism & Retina At Janssen Cardiovascular, Metabolism (CVM) & Retina, we take on the most pervasive diseases that burden hundreds of millions of people and healthcare systems around the world. As part of this long-standing ...
For Patients & Caregivers
Article Type: Infectious Diseases & Vaccines For Patients & Caregivers We are focused on tackling complex infectious diseases, finding the right paths of intervention, and ensuring they reach those in need. We are committed to empowering patients ...
Creating Treatments for Infectious Diseases
At Janssen, we have ambitious goals. We strive to discover and develop novel therapeutics and vaccines to treat and cure infectious diseases worldwide, improving treatment outcomes and patients’ lives. Our Fight Against Infectious Diseases Is a Global ...
About DIA
The Disease Interception Accelerator The Disease Interception Accelerator (DIA), part of Janssen Research & Development, LLC, is working to harness cutting-edge science to seek the most tractable interception opportunities to identify and address the ...
Late Development
Late Development “Our goal is to evolve the next wave of cancer therapies into comprehensive regimens that combine several approaches tailored to patients’ individual needs.” Craig Tendler, M.D. Vice President, Late Development and Global Medical Affairs ...
PH Partnering
Partner with Janssen in Pulmonary Hypertension Janssen is spearheading a new era for pulmonary hypertension (PH), working to transform the disease into a long-term manageable condition, so that patients can live a normal life. We are focusing our ...
Unique molecular properties of nipocalimab enabling differentiated potential in treating generalized myasthenia gravis to be presented at American Academy of Neurology’s 2024 Annual Meeting
Apr 11, 2024 United States Analysis of clinical and non-clinical studies supports the investigational treatment’s potential for rapid, deep and sustained immunoglobulin G (IgG) lowering DENVER, Co. (April 11, 2024) – Johnson & Johnson today announced ...